Marwân-Al-Qays Bousmah1,2, Marie Libérée Nishimwe3, Christopher Kuaban4, Sylvie Boyer3. 1. Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France. marwan-al-qays.bousmah@ird.fr. 2. Centre Population et Développement (Ceped), Institut de recherche pour le développement (IRD) & Université de Paris, Inserm ERL 1244, 45 rue des Saints-Pères, 75006, Paris, France. marwan-al-qays.bousmah@ird.fr. 3. Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France. 4. Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon.
Abstract
BACKGROUND: To foster access to care and reduce the burden of health expenditures on people living with HIV (PLHIV), several sub-Saharan African countries, including Cameroon, have adopted a policy of removing HIV-related fees, especially for antiretroviral treatment (ART). We investigate the impact of Cameroon's free antiretroviral treatment (ART) policy, enacted in May 2007, on catastrophic health expenditure (CHE) risk according to socioeconomic status, in PLHIV enrolled in the country's treatment access program. METHODS: Based on primary data from two cross-sectional surveys of PLHIV outpatients in 2006-2007 and 2014 (i.e., before and after the policy's implementation, respectively), we used inverse propensity score weighting to reduce covariate imbalances between participants in both surveys, combined with probit regressions of CHE incidence. The analysis included participants treated with ART in one of the 11 HIV services common to both surveys (n = 1275). RESULTS: The free ART policy was associated with a significantly lower risk of CHE only in the poorest PLHIV while no significant effect was found in lower-middle or upper socioeconomic status PLHIV. Unexpectedly, the risk of CHE was higher in those with middle socioeconomic status after the policy's implementation. CONCLUSIONS: Our findings suggest that Cameroon's free ART policy is pro-poor. As it only benefitted PLHIV with the lowest socioeconomic status, increased comprehensive HIV care coverage is needed to substantially reduce the risk of CHE and the associated risk of impoverishment for all PLHIV.
BACKGROUND: To foster access to care and reduce the burden of health expenditures on people living with HIV (PLHIV), several sub-Saharan African countries, including Cameroon, have adopted a policy of removing HIV-related fees, especially for antiretroviral treatment (ART). We investigate the impact of Cameroon's free antiretroviral treatment (ART) policy, enacted in May 2007, on catastrophic health expenditure (CHE) risk according to socioeconomic status, in PLHIV enrolled in the country's treatment access program. METHODS: Based on primary data from two cross-sectional surveys of PLHIV outpatients in 2006-2007 and 2014 (i.e., before and after the policy's implementation, respectively), we used inverse propensity score weighting to reduce covariate imbalances between participants in both surveys, combined with probit regressions of CHE incidence. The analysis included participants treated with ART in one of the 11 HIV services common to both surveys (n = 1275). RESULTS: The free ART policy was associated with a significantly lower risk of CHE only in the poorest PLHIV while no significant effect was found in lower-middle or upper socioeconomic status PLHIV. Unexpectedly, the risk of CHE was higher in those with middle socioeconomic status after the policy's implementation. CONCLUSIONS: Our findings suggest that Cameroon's free ART policy is pro-poor. As it only benefitted PLHIV with the lowest socioeconomic status, increased comprehensive HIV care coverage is needed to substantially reduce the risk of CHE and the associated risk of impoverishment for all PLHIV.
Authors: Chris D James; Kara Hanson; Barbara McPake; Dina Balabanova; Davidson Gwatkin; Ian Hopwood; Christina Kirunga; Rudolph Knippenberg; Bruno Meessen; Saul S Morris; Alexander Preker; Yves Souteyrand; Abdelmajid Tibouti; Pascal Villeneuve; Ke Xu Journal: Appl Health Econ Health Policy Date: 2006 Impact factor: 2.561
Authors: Ke Xu; David B Evans; Kei Kawabata; Riadh Zeramdini; Jan Klavus; Christopher J L Murray Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: Adam Wagstaff; Gabriela Flores; Justine Hsu; Marc-François Smitz; Kateryna Chepynoga; Leander R Buisman; Kim van Wilgenburg; Patrick Eozenou Journal: Lancet Glob Health Date: 2017-12-13 Impact factor: 26.763